Alpine Immune Sciences Inc (ALPN)
65.00
+0.04
(+0.06%)
USD |
NASDAQ |
May 17, 16:00
65.00
0.00 (0.00%)
After-Hours: 20:00
Alpine Immune Sciences Research and Development Expense (Annual): 80.90M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 80.90M |
| December 31, 2022 | 70.24M |
| December 31, 2021 | 58.74M |
| December 31, 2020 | 27.18M |
| December 31, 2019 | 35.85M |
| December 31, 2018 | 28.97M |
| Date | Value |
|---|---|
| December 31, 2017 | 10.63M |
| December 31, 2016 | 23.32M |
| December 31, 2015 | 16.05M |
| December 31, 2014 | 12.20M |
| December 31, 2013 | 13.14M |
| December 31, 2012 | 7.100M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
27.18M
Minimum
2020
80.90M
Maximum
2023
54.58M
Average
58.74M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Vertex Pharmaceuticals Inc | 3.163B |
| Eliem Therapeutics Inc | 15.41M |
| Regeneron Pharmaceuticals Inc | 4.439B |
| Vera Therapeutics Inc | 78.22M |
| Eyenovia Inc | 12.98M |